Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
about
Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss.Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugsRenal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylateTests of renal function in patients with quiescent colitis: effects of drug treatment.Drug therapy of ulcerative colitis5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint.Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gammaInterplay of endoplasmic reticulum stress and autophagy in neurodegenerative disorders.Renal effects of long-term treatment with 5-aminosalicylic acidOroileal transit of slow release 5-aminosalicylic acid.Inflammatory bowel disease--a radical view.Oroileal transit of 5-aminosalicylic acid.Mesalazine induced interstitial nephritis.5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα.
P2860
Q26777634-0120680E-D685-4FA9-B9CF-72F2425339F2Q28319792-7783FB1C-17CC-4249-8574-1D570DDD9DBFQ28360107-EC0CD3B6-06B6-4F37-9F0F-76986E7AF515Q33618202-535B29B3-E5F9-464B-8AC5-5E4AF1D6271AQ34396529-BF76B512-2FB2-4AC2-AE84-7344B91B9E19Q34403155-C4338756-EA66-4F69-8E0E-EB1828EDC7E4Q35728207-255915A4-429E-4CCB-932B-B23D76946099Q36055120-1845516D-DF5F-4B5A-91CF-C5C7E415EDB1Q36403491-129CBE17-AC27-4AF6-B66B-EA7B0402696EQ36810822-D2EB920F-4C58-4328-A498-6395468D4B02Q37223156-0A8A8B3C-1D1F-47DB-9983-4C69F06B400BQ41956890-263B0BC1-582E-438D-857B-87A889C2D070Q43212912-E934C432-F461-4980-BD4D-34C3DF10625AQ43213353-E89B48AF-FC18-438F-89F5-A50AF2C7669BQ43214172-850542A3-0ECA-479B-8B3A-63D54D5FE4ACQ48203795-78D165FE-F535-4577-BB53-93E23E834CA9
P2860
Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
description
1990 nî lūn-bûn
@nan
1990 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Topical and systemic availabil ...... d release preparations in man.
@ast
Topical and systemic availabil ...... d release preparations in man.
@en
Topical and systemic availabil ...... d release preparations in man.
@nl
type
label
Topical and systemic availabil ...... d release preparations in man.
@ast
Topical and systemic availabil ...... d release preparations in man.
@en
Topical and systemic availabil ...... d release preparations in man.
@nl
prefLabel
Topical and systemic availabil ...... d release preparations in man.
@ast
Topical and systemic availabil ...... d release preparations in man.
@en
Topical and systemic availabil ...... d release preparations in man.
@nl
P2093
P1476
Topical and systemic availabil ...... d release preparations in man.
@en
P2093
B A Jacobsen
E F Hvidberg
J Fallingborg
K Abildgaard
L A Christensen
S Bondesen
S H Hansen
S N Rasmussen
P304
P407
P577
1990-10-01T00:00:00Z